Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetic profiling of continuous-infusion piperacillin/tazobactam in critically ill ICU patients
NL-OMON39910Phase 4Active, not recruiting
- Sponsor
- University Medical Center Groningen
- Start
- Dec 2013
- Modality
- Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of piperacillin + tazobactam in Infection, sponsored by University Medical Center Groningen. Primary endpoints: Total bound plasma concentration of piperacillin, Unbound plasma concentration of piperacillin and 6 more. Started Dec 2013; status: active, not recruiting.
02
Drugs
piperacillin + tazobactam
03
Conditions
Infection
Beyond the preview
Go deeper on NL-OMON39910.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON39910.